RGC — Regencell Bioscience Holdings Limited

Regencell Bioscience Holdings Limited operates a Traditional Chinese medicine (TCM) bioscience company. It focuses on the research, development, and commercialization of TCM for the treatment of neurocognitive disorders and degeneration, primarily attention deficit hyperactivity disorder and autism spectrum disorder. The company was incorporated in 2014 and is headquartered in Causeway Bay, Hong Kong.

Sector

Healthcare

Industry

Drug Manufacturers - Specialty & Generic

Market Cap

$16.67B

P/E Ratio

-4652.11

Beta

2.07

52-Week Range

0.57895-83.6

Dividend Yield

$0.00

CEO

Yat-Gai Au

Employees

12

IPO Date

Jul 16, 2021

Exchange

NASDAQ